{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T16:00:07Z","timestamp":1779379207577,"version":"3.53.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson & Johnson","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s40801-025-00488-9","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T03:52:14Z","timestamp":1746071534000},"page":"189-199","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparative Analysis of Survival in Pulmonary Arterial Hypertension for Patients Treated with Selexipag in Clinical Practice (EXPOSURE Study)"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9225-1306","authenticated-orcid":false,"given":"Stefan","family":"S\u00f6derberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Escribano-Subias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciara","family":"Archey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Muller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias J.","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Gaine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"key":"488_CR1","doi-asserted-by":"publisher","first-page":"343","DOI":"10.7326\/0003-4819-115-5-343","volume":"115","author":"GE D'Alonzo","year":"1991","unstructured":"D\u2019Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991;115:343\u20139.","journal-title":"Ann Intern Med"},{"key":"488_CR2","doi-asserted-by":"publisher","first-page":"216","DOI":"10.7326\/0003-4819-107-2-216","volume":"107","author":"S Rich","year":"1987","unstructured":"Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med. 1987;107:216\u201323.","journal-title":"Ann Intern Med"},{"key":"488_CR3","doi-asserted-by":"publisher","first-page":"2102024","DOI":"10.1183\/13993003.02024-2021","volume":"59","author":"MM Hoeper","year":"2022","unstructured":"Hoeper MM, Pausch C, Gr\u00fcnig E, Staehler G, Huscher D, Pittrow D, et al. Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry. Eur Respir J. 2022;59:2102024. https:\/\/doi.org\/10.1183\/13993003.02024-2021.","journal-title":"Eur Respir J"},{"key":"488_CR4","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1164\/rccm.202009-3698OC","volume":"204","author":"A Boucly","year":"2021","unstructured":"Boucly A, Savale L, Ja\u00efs X, Bauer F, Bergot E, Bertoletti L, et al. Association between initial treatment strategy and long-term survival in pulmonary arterial hypertension. Am J Resp Crit Care. 2021;204:842\u201354. https:\/\/doi.org\/10.1164\/rccm.202009-3698OC.","journal-title":"Am J Resp Crit Care."},{"key":"488_CR5","unstructured":"NHS Digital. National audit of pulmonary hypertension. 13th Annual Report. https:\/\/files.digital.nhs.uk\/36\/B8B717\/NAPH%2013AR%20-%20Main%20Report%20v1.0.pdf. Accessed July 2023."},{"key":"488_CR6","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1056\/NEJM199602013340504","volume":"334","author":"RJ Barst","year":"1996","unstructured":"Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334:296\u2013302.","journal-title":"N Engl J Med"},{"key":"488_CR7","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/S0735-1097(02)02012-0","volume":"40","author":"O Sitbon","year":"2002","unstructured":"Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002;40:780\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"488_CR8","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.jacc.2017.12.010","volume":"71","author":"VV McLaughlin","year":"2018","unstructured":"McLaughlin VV, Hoeper M, Channick R, Chin K, Delcroix M, Gaine S, et al. Pulmonary arterial hypertension-related morbidity is prognostic for mortality. J Am Coll Cardiol. 2018;71:752\u201363. https:\/\/doi.org\/10.1016\/j.jacc.2017.12.010.","journal-title":"J Am Coll Cardiol"},{"key":"488_CR9","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","volume":"373","author":"O Sitbon","year":"2015","unstructured":"Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galie N, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373:2522\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1503184.","journal-title":"N Engl J Med"},{"key":"488_CR10","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s12325-023-02730-8","volume":"41","author":"A Muller","year":"2024","unstructured":"Muller A, Escribano-Subias P, Fernandes CC, Fontana M, Lange TJ, S\u00f6derberg S, Gaine S. Real-world management of patients with pulmonary arterial hypertension: insights from EXPOSURE. Adv Ther. 2024;41:1103\u201319. https:\/\/doi.org\/10.1007\/s12325-023-02730-8.","journal-title":"Adv Ther"},{"key":"488_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/pul2.12403","volume":"14","author":"S Gaine","year":"2024","unstructured":"Gaine S, Escribano-Subias P, Muller A, Fernandes CC, Fontana M, Remenova T, et al. Selexipag in patients with pulmonary arterial hypertension associated with connective tissue disease (PAH-CTD): real-world experience from EXPOSURE. Pulm Circ. 2024;14: e12403. https:\/\/doi.org\/10.1002\/pul2.12403.","journal-title":"Pulm Circ."},{"key":"488_CR12","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/ckj\/sfab158","volume":"15","author":"NC Chesnaye","year":"2022","unstructured":"Chesnaye NC, Stel VS, Tripepi G, Dekker FW, Fu EL, Zoccali C, Jager KJ. An introduction to inverse probability of treatment weighting in observational research. Clin Kidney J. 2022;15:14\u201320. https:\/\/doi.org\/10.1093\/ckj\/sfab158.","journal-title":"Clin Kidney J"},{"key":"488_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw323","volume":"109","author":"XI Yao","year":"2017","unstructured":"Yao XI, Wang X, Speicher PJ, Hwang ES, Cheng P, Harpole DH, et al. Reporting and guidelines in propensity score analysis: a systematic review of cancer and cancer surgical studies. J Natl Cancer Inst. 2017;109: djw323. https:\/\/doi.org\/10.1093\/jnci\/djw323.","journal-title":"J Natl Cancer Inst"},{"key":"488_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-036961","volume":"10","author":"M Samuel","year":"2020","unstructured":"Samuel M, Batomen B, Rouette J, Kim J, Platt RW, Brophy JM, Kaufman JS. Evaluation of propensity score used in cardiovascular research: a cross-sectional survey and guidance document. BMJ Open. 2020;10: e036961. https:\/\/doi.org\/10.1136\/bmjopen-2020-036961.","journal-title":"BMJ Open"},{"key":"488_CR15","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s40266-021-00876-0","volume":"38","author":"LJ Seppala","year":"2021","unstructured":"Seppala LJ, van de Loo B, Schut M, van Schoor NM, Stricker BH, Kenny RA, et al. A propensity score matched approach to assess the associations of commonly prescribed medications with fall risk in a large harmonized cohort of older ambulatory persons. Drugs Aging. 2021;38:797\u2013805. https:\/\/doi.org\/10.1007\/s40266-021-00876-0.","journal-title":"Drugs Aging"},{"key":"488_CR16","doi-asserted-by":"publisher","DOI":"10.4324\/9780203771587","volume-title":"Statistical power analysis for the behavioral sciences","author":"J Cohen","year":"2013","unstructured":"Cohen J. Statistical power analysis for the behavioral sciences. London: Routledge; 2013."},{"key":"488_CR17","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res. 2011;46:399\u2013424. https:\/\/doi.org\/10.1080\/00273171.2011.568786.","journal-title":"Multivar Behav Res"},{"key":"488_CR18","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/pds.3891","volume":"17","author":"International Society for Pharmacoepidemiology","year":"2008","unstructured":"International Society for Pharmacoepidemiology. Guidelines for good pharmacoepidemiology practices (GPP). Pharmacoepidemiol Drug Saf. 2008;17:200\u20138. https:\/\/doi.org\/10.1002\/pds.3891.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"488_CR19","unstructured":"The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. Guide on methodological standards in pharmacoepidemiology (revision 10). EMA\/95098\/2010."},{"key":"488_CR20","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.ijcard.2012.10.026","volume":"168","author":"MM Hoeper","year":"2013","unstructured":"Hoeper MM, Huscher D, Ghofrani HA, Delcroix M, Distler O, Schweiger C, et al. Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. Int J Cardiol. 2013;168:871\u201380. https:\/\/doi.org\/10.1016\/j.ijcard.2012.10.026.","journal-title":"Int J Cardiol"},{"key":"488_CR21","doi-asserted-by":"publisher","first-page":"2200879","DOI":"10.1183\/13993003.00879-2022","volume":"61","author":"M Humbert","year":"2023","unstructured":"Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2023;61:2200879. https:\/\/doi.org\/10.1183\/13993003.00879-2022.","journal-title":"Eur Respir J"},{"key":"488_CR22","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","volume":"43","author":"M Humbert","year":"2022","unstructured":"Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43:3618\u2013731. https:\/\/doi.org\/10.1093\/eurheartj\/ehac237.","journal-title":"Eur Heart J"},{"key":"488_CR23","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1161\/CIRCULATIONAHA.121.058635","volume":"146","author":"\u00c9 Tremblay","year":"2022","unstructured":"Tremblay \u00c9, Gosselin C, Mai V, Lajoie AC, Kilo R, Weatherald J, et al. Assessment of clinical worsening end points as a surrogate for mortality in pulmonary arterial hypertension: a systematic review and meta-analysis of randomized controlled trials. Circulation. 2022;146:597\u2013612. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.058635.","journal-title":"Circulation"},{"key":"488_CR24","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1007\/s12325-021-01898-1","volume":"39","author":"N Gali\u00e8","year":"2022","unstructured":"Gali\u00e8 N, Gaine S, Channick R, Coghlan JG, Hoeper MM, Lang IM, et al. Long-term survival, safety and tolerability with selexipag in patients with pulmonary arterial hypertension: results from GRIPHON and its open-label extension. Adv Ther. 2022;39:796\u2013810. https:\/\/doi.org\/10.1007\/s12325-021-01898-1.","journal-title":"Adv Ther"},{"key":"488_CR25","doi-asserted-by":"publisher","first-page":"4374","DOI":"10.1007\/s12325-022-02199-x","volume":"39","author":"R Souza","year":"2022","unstructured":"Souza R, Delcroix M, Gali\u00e9 N, Jansa P, Mehta S, Pulido T, et al. Long-term safety, tolerability and survival in patients with pulmonary arterial hypertension treated with macitentan: results from the SERAPHIN open-label extension. Adv Ther. 2022;39:4374\u201390. https:\/\/doi.org\/10.1007\/s12325-022-02199-x.","journal-title":"Adv Ther"},{"key":"488_CR26","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.healun.2011.08.019","volume":"30","author":"RL Benza","year":"2011","unstructured":"Benza RL, Seeger W, McLaughlin VV, Channick RN, Voswinckel R, Tapson VF, et al. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension. J Heart Lung Transplant. 2011;30:1327\u201333. https:\/\/doi.org\/10.1016\/j.healun.2011.08.019.","journal-title":"J Heart Lung Transplant"},{"key":"488_CR27","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/s2213-2600(16)30019-4","volume":"4","author":"HA Ghofrani","year":"2016","unstructured":"Ghofrani HA, Grimminger F, Grunig E, Huang Y, Jansa P, Jing ZC, et al. Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial. Lancet Respir Med. 2016;4:361\u201371. https:\/\/doi.org\/10.1016\/s2213-2600(16)30019-4.","journal-title":"Lancet Respir Med"},{"key":"488_CR28","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1378\/chest.10-0969","volume":"140","author":"LJ Rubin","year":"2011","unstructured":"Rubin LJ, Badesch DB, Fleming TR, Galie N, Simonneau G, Ghofrani HA, et al. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. Chest. 2011;140:1274\u201383. https:\/\/doi.org\/10.1378\/chest.10-0969.","journal-title":"Chest"},{"key":"488_CR29","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1007\/s12325-023-02711-x","volume":"41","author":"E Gr\u00fcnig","year":"2024","unstructured":"Gr\u00fcnig E, Rahaghi F, Elwing J, Vizza CD, Pepke-Zaba J, Shen J, et al. Oral treprostinil is associated with improved survival in FREEDOM-EV and its open-label extension. Adv Ther. 2024;41:618\u201337. https:\/\/doi.org\/10.1007\/s12325-023-02711-x.","journal-title":"Adv Ther"},{"key":"488_CR30","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.118.005095","volume":"12","author":"A Torbicki","year":"2019","unstructured":"Torbicki A, Bacchi M, Delcroix M, Farber HW, Ghofrani H-A, Hennessy B, et al. Integrating data from randomized controlled trials and observational studies to assess survival in rare diseases. Circ Cardiovasc Qual Outcomes. 2019;12: e005095. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.118.005095.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"488_CR31","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01325-2024","author":"KM Chin","year":"2024","unstructured":"Chin KM, Gaine SP, Gerges C, Jing Z-C, Mathai SC, Tamura Y, et al. Treatment algorithm for pulmonary arterial hypertension. Eur Respir J. 2024. https:\/\/doi.org\/10.1183\/13993003.01325-2024.","journal-title":"Eur Respir J"}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-025-00488-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-025-00488-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-025-00488-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T03:08:12Z","timestamp":1750129692000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-025-00488-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["488"],"URL":"https:\/\/doi.org\/10.1007\/s40801-025-00488-9","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,30]]},"assertion":[{"value":"20 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Johnson & Johnson.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Stefan S\u00f6derberg has received speaker and consultancy fees, and financial support for participation in scientific events from Johnson & Johnson and MSD. Pilar Escribano-Subias has received grants \/ research support from Ferrer and GlaxoSmithKline, consulting fees from Johnson & Johnson, Acceleron, Ferrer and MSD, payment or honoraria for lectures, presentations, speaker\u2019s bureaus, manuscript writing or educational events from Johnson & Johnson, MSD, Ferrer and AOT, has received support from Johnson & Johnson and MSD for attending meetings and\/or travel, and has participated on a Data Safety Monitoring Board or Advisory Board for Johnson & Johnson, MSD, Ferrer, Gossamer, AOT, Acceleron and GlaxoSmithKline. Ciara Archey is an employee of Johnson & Johnson and has Johnson & Johnson shares. Audrey Muller is an employee of Johnson & Johnson and has Johnson & Johnson shares. Martina Fontana is an employee of Johnson & Johnson and has Johnson & Johnson shares. Tobias J. Lange has received speaker fees and\/or consultancy fees and\/or financial and non-financial support for participation in scientific events and\/or participated on a Data Safety Monitoring Board or Advisory Board for Acceleron Pharma Inc, AOP orphan pharmaceuticals, Bayer, BMS, B\u00f6hringer Ingelheim, CGI medicare, Ferrer, Gossamer Bio, Johnson & Johnson, MSD, and Pfizer. Sean Gaine has had relations, such as funding, with the following subjects that have commercial interests in the pharmaceutical and medical field: Aerovate Therapeutics, Acceleron Pharma Inc, Altavant, Gossamer Bio, Johnson & Johnson, MSD and United Therapeutics.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"These data are not currently publicly available for sharing, requests for sharing can be sent to the corresponding author and will be evaluated on an individual basis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The study was conducted in compliance with the Declaration of Helsinki and the protocol was approved at each study site (and at the national level in Sweden) by an Institutional Review Board or Independent Ethics Committee (Table , see ESM). The study was conducted in accordance with the International Society for Pharmacoepidemiology Guidelines for Good Pharmacoepidemiology Practices and the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance Guide on Methodological Standards in Pharmacoepidemiology.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained for each patient for accessing and processing anonymized patient data and their use in scientific research.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate and for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Stefan S\u00f6derberg, Pilar Escribano-Subias, Ciara Archey, Tobias J. Lange and Sean Gaine contributed to the conceptualization, writing \u2013 original draft and writing \u2013 reviewing and editing. Audrey Muller contributed to the conceptualization, data curation, formal analysis, methodology, writing \u2013 original draft and writing \u2013 reviewing and editing of the manuscript. Martina Fontana contributed to the data curation, formal analysis, validation, writing \u2013 original draft and writing \u2013 reviewing and editing. All authors read and approved the final manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}